NASDAQ:PYXS - Nasdaq - US7473241013 - Common Stock - Currency: USD
1.26
+0.16 (+14.55%)
The current stock price of PYXS is 1.26 USD. In the past month the price increased by 34.69%. In the past year, price decreased by -71.23%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.33 | 351.09B | ||
AMGN | AMGEN INC | 13.55 | 151.20B | ||
GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.56B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
NTRA | NATERA INC | N/A | 21.18B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
BIIB | BIOGEN INC | 7.81 | 18.10B |
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The company is headquartered in Boston, Massachusetts and currently employs 44 full-time employees. The company went IPO on 2021-10-08. The firm is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
PYXIS ONCOLOGY INC
321 Harrison Avenue
Boston MASSACHUSETTS US
Employees: 55
Company Website: https://pyxisoncology.com/
Investor Relations: http://ir.pyxisoncology.com
Phone: 16172219059
The current stock price of PYXS is 1.26 USD. The price increased by 14.55% in the last trading session.
The exchange symbol of PYXIS ONCOLOGY INC is PYXS and it is listed on the Nasdaq exchange.
PYXS stock is listed on the Nasdaq exchange.
14 analysts have analysed PYXS and the average price target is 7.34 USD. This implies a price increase of 482.86% is expected in the next year compared to the current price of 1.26. Check the PYXIS ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PYXIS ONCOLOGY INC (PYXS) has a market capitalization of 77.60M USD. This makes PYXS a Micro Cap stock.
PYXIS ONCOLOGY INC (PYXS) currently has 55 employees.
The Revenue of PYXIS ONCOLOGY INC (PYXS) is expected to decline by -100% in the next year. Check the estimates tab for more information on the PYXS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PYXS does not pay a dividend.
PYXIS ONCOLOGY INC (PYXS) will report earnings on 2025-05-09, before the market open.
PYXIS ONCOLOGY INC (PYXS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.95).
The outstanding short interest for PYXIS ONCOLOGY INC (PYXS) is 15.24% of its float. Check the ownership tab for more information on the PYXS short interest.
ChartMill assigns a technical rating of 2 / 10 to PYXS. When comparing the yearly performance of all stocks, PYXS is a bad performer in the overall market: 92.29% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to PYXS. The financial health of PYXS is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months PYXS reported a non-GAAP Earnings per Share(EPS) of -0.95. The EPS increased by 48.65% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -49.2% | ||
ROE | -64.04% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 86% to PYXS. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -20.25% and a revenue growth -100% for PYXS